TCM
WGS icon

Tuttle Capital Management’s GeneDx Holdings WGS Stock Holding History

Tuttle Capital Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-745
Closed -$31K – 103
2022
Q2 		$31K Buy
+745
New +$50.5K 0.09% 86
2021
Q1 		– Sell
-1,338
Closed -$487K – 318
2020
Q4 		$487K Buy
+1,338
New +$466K 0.38% 80

Other funds holding WGS

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
TP
Third Point New York $4.68B AUM 37.3% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Tuttle Capital Management's WGS Position: Q3 2022 in Review

Tuttle Capital Management sold out of GeneDx Holdings (WGS) in Q3 2022, closing a stake of 745 shares — an estimated $31K sold.

Tuttle Capital Management first reported a position in WGS in Q4 2020 and held it in 2 quarters. The position peaked at $487K in Q4 2020. 98 funds tracked by Wall St. Rank hold WGS as of Q3 2022.

  • Tuttle Capital Management reported no remaining GeneDx Holdings position as of Q3 2022 after selling out during the quarter.
  • Tuttle Capital Management sold 745 GeneDx Holdings shares in Q3 2022, an estimated $31K.
  • Tuttle Capital Management first reported a position in GeneDx Holdings in Q4 2020 and held it in 2 quarters.
  • Tuttle Capital Management's GeneDx Holdings position peaked at $487K in Q4 2020.
  • 98 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2022.

Based on Tuttle Capital Management's 13F filing for Q3 2022, filed 11 Oct 2022.